LON:DXRX

Diaceutics Interim Earnings Results & Report

Diaceutics logo
GBX 182 -8.00 (-4.21%)
As of 11/20/2026 12:33 PM Eastern

Diaceutics reported Interim earnings on September 23, 2025. The company reported EPS of -GBX 2.84.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

Diaceutics EPS Results

Actual EPS
-GBX 2.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Diaceutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Diaceutics Interim Earnings FAQ

Diaceutics (LON:DXRX) reported earnings of -GBX 2.84 per share for Interim. The report was announced on Tuesday, September 23, 2025.

Diaceutics Earnings Headlines

Diaceutics (LON:DXRX) Stock: Insider Jordan Clark Sells 250,000 Shares
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Canaccord Genuity Group Reaffirms Buy Rating for Diaceutics (LON:DXRX)
Diaceutics (LON:DXRX) Stock Falls 1.4% - Here's Why
See More Diaceutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Diaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Diaceutics and other key companies, straight to your email.

About Diaceutics

At Diaceutics (LON:DXRX) we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

View Diaceutics Profile